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Circulating immune complexes in adults with idiopathic ne-
phrotic syndrome. A retrospective analysis of the prevalence of
circulating immune complexes in adults with idiopathic nephrot-
ic syndrome was conducted. Immune complexes were detected
by the fluid and solid-phase Clq-binding and the Raji cell assays.
Adults with idiopathic nephrotic syndrome were categorized by
renal pathology as follows: minimal change disease (N = 14),
focal glomerular disease (N = 27), and membranous nephropa-
thy (N = 55). Patients were randomized into prednisone- and
placebo-treated groups. Immune complexes as determined by re-
activity in one or more assay techniques were more prevalent in
patients with minimal change (11/14), focal glomerular disease
(13/27), and membranous nephropathy (26/55) as compared with
control sera (P <0.001). The presence of immune complexes by
any assay or a combination of assays did not predict remission of
the nephrotic syndrome. There was no difference in the preva-
lence of immune complexes between prednisone- and placebo-
treated groups. The demonstration of immune complexes in min-
imal change disease, membranous nephropathy, and focal gb-
merular disease is consistent with the suspected immunologic na-
ture of these disorders; it does not necessarily define, however, a
specific pathogenic role for the circulating immune complexes
detected by these assays. The presence of immune complexes
was not specific for a particular disease category, and therefore
was not helpful diagnostically. In addition, their presence did not
correlate with relapses or remissions of the nephrotic syndrome
or the decline of renal function.
Complexes immuns circulant chez l'adulte atteint de syndrome
nephrotique. Une analyse retrospective de Ia fréquence des com-
plexes immuns circulants chez l'adulte atteint de syndrome
nephrotique idiopathique a été réalisée. Les complexes immuns
ont Cte détectCs par la liaison de Clq en phase solide et au moyen
des cellules de Razi. Les adultes atteints de syndrome nephro-
tique ont été classes en fonction de Ia morphologie rénale de Ia
facon suivante: modifications minimes (N = 14), atteinte glomer-
ulaire focale (N = 27), et glomerulite extramembraneuse (N =
55). Les inalades ont etC rCpartis en deux groupes de traitements
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par Ia prednisone ou au placebo. Les complexes immuns évaluds
par la réactivité dans une ou plusieurs techniques de mesure ont
été plus frequents chex les malades ayant des modifications mm-
imes (11/14). une atteinte glomerulaire focale (13/27), et une
glomerulite extramembraneuse (26/55) par comparaison avec les
résultats obtenus pour des serums contrôles P <0,001). La pré-
sence des complexes immuns par Fune quelconque des tech-
niques ou une combinaison de techniques ne permet pas de pré-
voir La remission du syndrome nephrotique. II n'y avait pas de
difference dans Ia frequence des complexes immuns entre les
groupes traités par Ia prednisone ou le placebo. La mise en évi-
dence de complexes immuns au cours de lesions glomerulaires
minimes, de Ia glomerulite extramembraneuse et des lesions
glomerulaires focales est compatible avec Ia nature immunolo-
gique soupconnée de ces désordres, mais n'assigne pas de role
pathogenique specifique aux complexes immuns circulants mis
en evidence par ces techniques. La presence de complexes im-
muns n'est pas specifique dune variétd particulière d'atteinte
rénale et, par consequent, n'aide pas au diagnostic. De plus, La
presence de complexes immuns n'est pas corrélée avec les re-
chutes ou les remissions du syndrome nephrotique ou La diminu-
tion de Ia fonction rénale.
An immune complex pathogenesis of many
idiopathic forms of human glomerulonephritis has
been accepted primarily on the basis of the pattern
of immunoglobulin deposition observed by immu-
nofluorescent studies. The granular pattern of im-
munoglobulin deposition resembles that observed
in various animal models of glomerulonephritis in
which glomerular immune complex deposition can
be proven to be pathogenically important. The dem-
onstration of circulating immune complexes (CIC)
in idiopathic forms of human glomerulonephritis
would be consistent with the proposed immune
complex pathogenesis of these disorders.
Recent advances in technology have provided a
variety of methods for the detection of CIC. The
presence of CIC in nephritic forms of glomerulone-
phritis has previously been documented by our lab-
oratory [1]; thus, an extension to include the ne-
phrotic forms of glomerulonephritis was under-
taken. In 1972, investigators from 17 institutions
joined to evaluate the influence of prednisone thera-
py on the outcome of adult patients with idiopathic
nephrotic syndrome. During the conduct of this
study, serial serum samples were obtained and
stored frozen in a central reference laboratory. Sub-
sequently, it was decided to determine the preva-
lence of CIC in this group of patients and to cone-
late the presence of immune complexes with clinical
disease activity, rate of decline of renal function,
and response to therapy. The detailed character-
istics of this patient population and the response to
therapy are described in a separate manuscript [2].
This report describes a multiassay, fluid (FC1q) and
solid phase (SCIq) Clq binding and Raji cell (RCA)
radioimmune assays, approach to the determination
of CIC and their relationship to the underlying pa-
thology of idiopathic nephrotic syndrome. Further-
more, it evaluates the usefulness of immune com-
plex detection in prognostic and therapeutic aspects
of this disorder.
Methods
Adult patients, aged 16 to 65 years, presenting
with idiopathic nephrotic syndrome were entered
for study. All patients had protein excretion > 4g
per 24 hours and creatinine clearances > 90 liters!
day!l .73 m2 and had received no prior steroid or im-
munosuppressive therapy. Appropriate studies al-
lowed exclusion of systemic illnesses such as sys-
temic lupus erythematosus, diabetes mellitus, amy-
loidosis, multiple myeloma, sickle cell disease,
infection, or drug reaction. No patient had clinical
signs of renal vein thrombosis; angiography was not
routinely performed, however, to exclude this diag-
nosis. Histologic categorization of the renal lesion
was based on light, immunofluorescent, and elec-
tron microscopic examination by a group of six con-
sulting renal pathologists.2 Patients were random-
ized into treatment (alternate day prednisone for 8
weeks) and placebo groups.
As of September 30, 1977, we had serum samples
from 114 of the 172 patients entered into the study.
Histologic categorization revealed 14 with mini-
mal change disease (MCD), 27 with focal glomeru-
lar disease (FGD) (22 with focal and segmental gb-
merulosclerosis and hyalinosis, 5 with other focal
lesions), and 55 with membranous nephropathy
(MN). The remaining 18 patients had a variety of
renal lesions. The number in each subgroup of these
18 patients was too small for evaluation; thus they
are excluded from this report. Clinical remissions of
the nephrotic syndrome are defined as follows. A
partial remission is a reduction in 24-hour protein
excretion to between 150 mg and 2 g. A complete
remission is a reduction to less than 150 mg. Guide-
lines for discontinuation of a patient from study pro-
tocol were based on "stop points." A creatinine
'stop-point" occurred when there was a decrease
in creatinine clearance to one half or less of the orig-
inal value or a doubling of the serum creatinine.
Serum samples. Blood was collected by each of
the participating institutions from patients at entry,
2 months, 6 months, 1 year, and then yearly after
2Doctors P. M. Burkholder. J. Churg, R. Cotran, V. Pinn, S.
Rosen, and B. Spargo
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entry into the study. By sterile technique, serum
samples were separated by centrfugation, added in-
to a tube with 0.05% sodium azide, and mailed un-
frozen to our laboratory. Participants were instruct-
ed to store serum at 40 C for no more than a few
days prior to being mailed "Air-Mail, Special Deliv-
ery." On receipt, the serum samples were aliquoted
and stored at —70° C. All sera samples were sub-
sequently thawed once, aliquoted, refrozen at
—70° C, and an aliquot of each sample was shipped
frozen to the laboratory where the Raji cell assay
was performed (Dr. Clive Hall, Massachusetts Gen-
eral Hospital). One to eight serial samples were
available per patient, and a total of 235 sera samples
were studied (35 MCD, 60 FGD, and 140 MN). Sera
samples were stored from 1 to 6 years prior to the
CIC determinations.
Controls: Normal control sera. Serum samples
from 50 healthy laboratory personnel were eval-
uated by FC1q and SC1q assays. Ten samples were
assayed within 2 months of collection; the remain-
ing 40 were stored at —70° C for periods up to 18
months prior to assay. Sera samples from 47 other
healthy laboratory personnel were evaluated by the
RCA after less than 6 months of storage at —70° C.
Statistical evaluation of these samples determined
the upper limit of normal reactivity for each of the
dC assays.
Azide control sera. Twelve sera samples from
healthy laboratory personnel had 0.05% sodium
azide added. Aliquots of each were stored for vari-
ous periods of time at room temperature, 4° C,
or —20° C prior to storage. These sera samples
were assayed after 4 months of —70° C storage
by both the FC1q and SC1q assays. These controls
were evaluated to determine the effect of the addi-
tion of azide and variable temperature storage.
Frozen-thawed, stored sera. Twenty-three addi-
tional sera samples from laboratory personnel
stored at —20° C for 4 years, which had been re-
peatedly frozen and thawed, were evaluated by all
three assay techniques. These samples were includ-
ed to determine the effect of adverse storage and
handling conditions, as no concurrently collected
and stored normal sera were available to compare
with the sera samples from the nephrotic subjects.
They were also included for comparison of assay
results by all three assay techniques.
Shared SLE sera. Thirteen sera samples from pa-
tients with systemic lupus erythematosus (SLE)
were shared between laboratories for comparison of
assay reactivity in a population, other than the
study population, known to have dC.
Immune complex assays: Raji cell assay (RCA).
The Raji cell radioimmunoassay was performed as a
modification of the method of Theofilopoulous, Wil-
son, and Dixon [3] and has been previously de-
scribed [4].
Fluid-phase Clq-binding assay (FC1q). This assay
was performed as a modification of the method of
Nydegger et al [5]. Of test serum samples, 200 jsl
were added to 100 pi of veronal buffered saline
(VBS) and heated at 56° C for 30 mi After it was
cooled to room temperature, 0.5 pg 1251-Clq [6, 7] in
100 jsl of 1% bovine serum albumin (BSA)-VBS was
added to the reaction mixture; this mixture was in-
cubated at 37° C for 30 mm. The dId were twice
precipitated at 4° C with 2.5% polyethylene glycol
(mol wt, 6000 daltons, Union Carbide). The precipi-
tate was isolated by centrifugation (2400 rpm, 4° C,
30 mm), and the precipitated radioactivity was
counted in an automatic Beckman 7000 gamma
counter. Heat-aggregated human gammaglobulin
(AHG) in serial dilutions from 2300 g!ml to 500 ng/
ml in VBS was added to 200 l of NHS; this mixture
was assayed as above to provide a standard curve.
Test sera samples were run in duplicate, compared
to the standard curve of AHG. and the results of the
mean of two determinations were expressed as mi-
crograms per milliliter of AHG equivalents.
Solid-phase Clq-binding assay (SCIq). This assay
was performed as a modification of the method of
Hay, Nineham, and Roitt [8]. Each 12 x 75-mm
polystyrene tube (Falcon. Oxnard, California) was
incubated at 4° C for 20 hours with 1 ml of 5 jsg/ml
phosphate buffered saline solution (PBS) of freshly
isolated human Clq [6]. The tubes were washed
three times with PBS, incubated for 2 hours at room
temperature with 1.5 ml of 1% BSA-PBS. washed
three more times with PBS, and stored at —70° C
prior to use.
Of the test sera samples, 50 pi were added to 100
pJ 0.2 M EDTA (pH, 7.4); this mixture was in-
cubated at 37° C for 30 mm. Of this solution, 60 l
were added to 940 j.tl of PBS into a Clq-coated tube;
then, this mixture was incubated at 37° C for 1 hour
and at 4° C for 20 hours. The protein not bound to
the tube was eliminated by washing with PBS. We
added 2.5 pg of '251-rabbit anti-human IgG [7] in 1
ml of 1% BSA-PBS to the tube and incubated it at
37° C for 1 hour and at 4° C for 30 mm. Unbound
protein was again eliminated by washing with PBS.
and bound radioactivity was counted. AHG in serial
dilutions from 1000 g/ml to 500 ng/ml suspended in
NHS were assayed as above to produce a standard
curve. Test sera samples, run in duplicate, were
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compared to the standard curve, and the mean val-
ue of the two determinations was expressed as mi-
crograms per milliliter of AHG equivalents. For all
three assays, AHG was prepared by the method of
Mauer et al [9]. Upper limits of normal for each as-
say were set at two standard deviations above the
mean value of the normal control sera. The upper
limits of normal, expressed as micrograms per mil-
liliter of AHG equivalents were RCA < 15 jLg/ml,
FCIq <25 sg/ml, and SClq < 20 /Lg/mI.
Statistical analysis. Correlations between assays,
prevalence of positive assays in the study popu-
lation compared to the controls, and relationships
of assay positivity to remission of the nephrotic
syndrome and change in renal function were ana-
lyzed by the x2 test. For analysis of relationships of
assay positivity to histologic category and treat-
ment group, data were arranged in a 2 x 2 x 3 table,
and the frequencies were computer-fitted to a log-
linear model. Results did not require analysis of
second order interactions as the presence of im-
mune complexes, histologic lesion, and treatment
were independent events.
Results
Patient characteristics. Patients were classified
according to histologic characteristics as follows:
MCD (14), FGD (27), and MN (55). Approximately
equal numbers of patients in each category received
an 8-week course of alternate-day prednisone thera-
py or a placebo. None of 14 patients (0/14) with
MCD, 6/27 patients with FGD, and 9/55 patients
with MN reached creatinine stop points" during
the study period. Partial remissions of the nephrotic
syndrome occurred in 2 patients with MCD, 2 with
FGD, and 18 with MN. Complete remissions of the
nephrotic syndrome occurred in 8 patients with
MCD. 5 with FGD, and 10 with MN.
Prevalence of ('IC in control sera (Table 1). The
number of normal control sera samples with detect-
able CIC were consistent with the statistically de-
termined upper limit of normal. No false positivity
induced by the addition of azide was demonstrated.
The prevalence of positive assay results in the fro-
zen-thawed sera samples, which had been variably
stored, was slightly higher than that in the normal
control sera samples. Positive samples in control
sera were scattered throughout the range of positiv-
ity, as were the study samples (Fig. 1). The range of
AHG equivalents (in micrograms per milliliter) is
given in Table I.
Prevalence of CIC in idiopathic nephrotic syn-
drome (INS) (Table 2). The prevalence of CIC in all
patients at entry, as well as each of the histologic
categories, is significantly different from normal
controls as determined by x2 analysis with the ex-
ception of MN patients evaluated by the RCA. CIC
were detected, however, by the RCA assay in at
least one sample in 12/55 patients with MN as com-
pared with 2/47 normal controls (x2 = 6.67, P <
0.01). The percentage of patients positive fluctuated
in time during the study period as did the positivity
of individual patients. At all times, CIC were more
prevalent than they were in normal control sera
samples. Eleven of fourteen (79%) patients with
MCD, 16/27 (59%) patients with FGD, 37/55 (67%)
patients with MN, and 63/97 (65%) of all patients
with INS were positive by one or more assay tech-
niques on at least one occasion. Table 2 summarizes
all data on patients with INS. Observations in our
laboratory have shown that not more than 15% of 10
healthy controls are positive when evaluated at
monthly intervals over 18 months by both FCIq and
SClq. There was a wide range in degree of positivity
by all assay techniques (Fig. 1).
Effect of storage on assay positivity (Table 3). As
there was no control population having sera sam-
Table 1. Results of circulating immune complexes in control sera
Number positive
N FCIq SCIq RCA Any
Normal controls
Range
50 1
<25 to 60
2
<20to55
2/47a
<15 to 20
5/97
Frozen-thawed-stored sera
Rangeb
23 0
<25
3
<20to70
2
<15to47
5
Shared SLE
Range
13 8
<25 to 480
8
<2Oto 100
12
<15 to 3250
13
Azide controls 12 0 0 — —
a Results on 47 sera not shared between laboratories
Range of positivity in sg/ml of AHG equivalents
SLE is systemic lupus erythematosus.
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Parentheses i'ith subscript denote
pies handled and stored in a manner identical to the
experimental sera, the prevalence of positivity as a
function of storage time was assessed as an internal
control. The prevalence of positivity was not signif-
icantly different in those sera samples stored for
longer periods as compared to those samples stored
for shorter periods of time. Samples from the fro-
zen-thawed-stored sera had a slightly higher preva-
lence of CIC than did the normal control sera (not
statistically significant, x2 = 0.98).
Relationship of CIC results and clinical charac-
teristics. At the time of entry into the study and at 2
and 6 months after entry, there was no statistical
difference in prevalence of CIC between the predni-
sone- and placebo-treated groups. Thus, prednisone
did not exert an apparent effect on the presence of
CIC as measured by any of the three assay tech-
niques. In addition, the presence of CIC did not cor-
relate with remission of the nephrotic syndrome,
rate of decline of renal function, or creatinine stop-
points."
Correlations between assays. There was no cor-
relation between any of the assays in MCD. In both
FGD and MN, there was a correlation between the
SClqandRCA(2=7.1,P<0.0l;2= l2.4,P<
0.001, respectively), as well as in all patients with
idiopathic nephrotic syndrome (x2 = 19.2, P <
0.001). The FClq did not correlate with the SClq or
RCA in any category.
Discussion
The results of this study demonstrate an in-
creased prevalence of CIC in adults with idiopathic
nephrotic syndrome in which the underlying lesions
were minimal change, focal glomerular, and mem-
branous disease. It further demonstrates that levels
of CIC fluctuate with time in the individual patient
as well as in populations of patients.
Of the 14 adults with MCD in the present study,
79% had detectable CIC that bind complement by
one or more assay techniques. Stuhlinger, Ver-
roust, and Morel-Maroger [10] found similar re-
sults, as 10/12 MCD patients were positive by the
guinea pig macrophage uptake inhibition assay.
With the CIq deviation test, Sobel, Gabay, and
Lagrue [11] found 8/19, and Simpson et al [12] found
2/8 MCD patients to be positive. On the other hand,
the presence of cryoglobulins, which in some cir-
cumstances represent CIC, has not been demon-
strated in MCD [13, 14]. With the inhibition of ag-
glutination of immunoglobulin-coated latex parti-
cles, Levinsky et al [15] recently reported that 17/18
children with steroid-responsive nephrotic syn-
drome in relapse (presumably minimal change dis-
ease) had detectable IgG-containing immune com-
plexes that disappeared with remission of the ne-
phrotic syndrome. They failed to find Clq-binding
immune complexes in these children. Smith et a!
[16] have found similar changes in children, with an
assay based on C3b-mediated inhibition of lympho-
cyte rosette formation. Fourteen of fourteen (14/14)
children in relapse were positive for dC, whereas
9/34 were positive while in remission. Both the So-
bel et al study [11] and the present study demon-
strate Clq-binding CIC in adults with MCD and fail
to show a correlation with relapse of the nephrotic
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syndrome. Furthermore, with the FC1q and SC1q
assays, we failed to detect CIC in 45 samples from
12 children with MCD either in remission or relapse
(Abrass et a!: unpublished observations). These dis-
crepancies may suggest a difference in the character
of the CIC present in children as opposed to adults
with MCD, and unsuspected heterogenicity of
mechanisms in nephrotic syndrome associated with
minimal changes by light microscopy, or may sim-
ply reflect the differences in detection character-
istics of various assays [17]. In spite of these con-
troversies, CIC are detectable in MCD by a variety
of assay techniques. As MCD is conventionally de-
fined by the lack of immunoglobulin and com-
plement deposits in glomeruli, the significance of
CIC in MCD is yet to be determined. It is possible
that CIC may influence the development of protein-
uria in MCD, while not depositing in the glomeru-
lus.
In the present study, 13/27 patients with FGD had
detectable CIC by one or more assay techniques. Of
55 patients studied by other investigations, 24 were
positive by a variety of assay techniques [1,10,
12,13,16,18]. Fifteen of thirty one (50%) of those pa-
tients who were negative were evaluated only for
cryoimmunoglobulins. The remainder of investiga-
tors detected CIC in a majority of patients with
FGD. In keeping with the findings by immuno-
fluorescence of immunoglobulin and complement
Table 2. Immune complex results in adults with idiopathic
nephrotic syndromea
Diagnosis
Time of
sampling FClq SClq RCA
Any
assay
MCD(N= 14) Entry
2mo
6mo
Anytime
4/j45
2/9
0/2
5/14
7/14k
2/9
1/4
10/14
4/l4
4/10
1/3
4/14
11/l4
6/10
2/4
11/14
FGD (N = 27) Entry
2mo
6mo
Anytime
5/27b
3/17
2/11
7/27
9/26k
11/17
4/8
15/27
6/26b
5/17
5/9
6/27
13/27e
12/17
6/11
16/27
MN )N = 56) Entry
2mo
6 mo
Anytime
14/55b
10/44
3/27
21/56
22/52c
13/38
9/25
32/55
8/54
6/39
4/26
12/55
26/55
21/44
12/27
37/56
All patients Entry 23196b 3192b 18/94 50/96(N = 97) Anytime 33/97b 57/96c 22/96 64197c
a Numberator is the number positive; denominator is number
of patients tested; N is the number of patients; any" denotes
positive result by one or more assay techniques. For time of sam-
pling, anytime" means that all samples were collected at entry,
at 2 months, at 6 months, or at any other time that samples were
available. MCD is minimal change disease; FGD, focal glomeru.
lar disease; and MN, membranous nephropathy.
b P < 0.005, vs. controls.
P < 0.001, vs. controls.
deposits in glomeruli of patients with FGD. the
presence of CIC is consistent with an IC pathogene-
sis of this lesion. The 1gM and C3 deposits charac-
teristically present in areas of focal sclerosis [19]
may represent nonspecific trapping of protein rather
than deposition from the circulation. As there are
no carefully studied animal models of FGD, little is
known of factors that influence its development.
The results of CIC detection in MN have been
quite variable. Of the patients presented here, 47%
had detectable CIC by one or more assay tech-
niques at entry into the study. Sixty-six percent had
positive assay results on at least one occasion dur-
ing the study period. Of 143 patients, 43 (30%) stud-
ied by other investigators were positive by a variety
of assay techniques. dC were detected by
cryoimmunoglobulins (1/12 patients [13], 4/10 pa-
tients [5]), inhibition of uptake by guinea pig macro-
phages (6/7 patients [10]), and inhibition of lympho-
cyte rosette formation (8/26 patients [18]), Clq bind-
ing assay (1/10 patients [20]), and the Clq deviation
test (18/26 patients [11]). Ooi, Ooi, and Pollak [21],
Simpson et at [12], and Woodroffe et al [1] failed to
demonstrate CIC by other complement-dependent
assays in evaluating smaller numbers of patients
with membranous nephropathy. Tung et a! [22]
evaluated 8 patients with MN and found none posi-
tive by the RCA and only one positive by the FClq
assay. Zager et al [23] found only 1 of 21 patients
with idiopathic MN to have detectable CIC by the
RCA. The absence of detectable CIC by the RCA is
consistent with our findings where a trend toward
an increased prevalence at entry into the study was
noted but was not statistically significant. It appears
that the RCA may be less sensitive or specific for
those CIC in MN that are detected by other assay
techniques.
The discrepancies between laboratories in detect-
ing CIC have further contributed to the controversy
regarding the pathogenesis of MN. The finding of
capillary wall deposits of Ig and complement sug-
gested an IC pathogenesis. The detection of CIC
would support this concept. The recent suggestion
Table 3. Number of samples positive by each assay as a function
of storage timea
Storage time, yr FCIq SCIq RCA
<4 9(N=24) 6(N=2l) 2(N=18)
2to4 7 (N = 43) 13 (N 47) 9 (N = 47)
<2 8(N=4l) 18(N=38) 11 (N=38)
a There were no significant differences by x2 analysis. FCIq is
fluid-phase Clq-binding assay; SClq, solid-phase Clq-binding as-
say; RCA, Raji cell assay.
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that membranous nephropathy results from in situ
formation of immune complexes [24-26] would be
supported, however, by the lack of detectable CIC.
This discrepancy in prevalence of CIC in MN is not
surprising, because such a variety of assay tech-
niques has been applied; it remains to be adequately
clarified, however. An alternative explanation is
that detectable CIC are more common in patients
with severe nephrotic syndrome early in the course
of the disease, when their GFR's are relatively nor-
mal. Many patients with membranous nephropathy
have lesser degrees of proteinuria than those en-
tered into this study. A portion of the placebo-
treated patients had a relatively rapid decline in re-
nal function during the first year of study. This sug-
gests that the population presented here may repre-
sent a subset of patients with membranous nephrop-
athy in which CIC are more prevalent. Factors that
argue against this include: (a) CIC were equally
common in prednisone- and placebo-treated groups
and (b) CIC were equally as common in patients
with and without remission of the nephrotic syn-
drome. There was a tendency, although not statisti-
cally significant, for CIC to be detected more fre-
quently in patients with a poorer outcome.
Although CIC were not as common in MN as has
been reported for lupus [1] and poststreptococcal
glomerulonephritis [27], in which an IC pathogene-
sis is more widely accepted, 37/56 (66%) of patients
and 70/140 (50%) of samples had detectable CIC. As
Ig and complement slowly accumulate in the sub-
epithelial space of patients with MN, intermittently
detectable CIC would be consistent with what is ob-
served in the glomerulus. The findings would also
be consistent with low levels of antibody produc-
tion with in situ binding.
In addition to the significance of CIC in specific
histologic categories, several general questions are
raised by the present study. A poor correlation be-
tween different assays was observed. CIC may be
composed of different antigens bound to immuno-
globulin having varying capacity to fix complement.
They may be formed in a range of antigen-antibody
ratios, and it is likely that a spectrum of CIC will
be present in any disease state. Casali et al [28] have
shown the FCIq is more likely to detect CIC formed
at relative antigen excess, whereas the RCA is more
likely to detect CIC formed at relative antibody ex-
cess. This could account for the lack of correlation
we observed between the FC1q and RCA. Although
no direct relationship has been established for the
SCIq and RCA with preformed CIC, the correlation
between SC1q and RCA in this study suggests simi-
lar performance of these two assays. Lack of corre-
lation between assays in given samples may reflect
level as well as heterogeneity of the existent CIC.
This was also demonstrated when a large number of
samples were shared between laboratories applying
18 methods for the detection of CIC [17]. It is im-
portant to note that the panel of assays applied in
this study should detect CIC formed in a range of
antigen-antibody ratios; noncomplement-binding
CIC would be missed, however.
A weakness in the present study is the lack of
concurrent control sera. We attempted to overcome
this limitation by the inclusion of various controls
(frozen-thawed-stored sera) to determine the maxi-
mum false positivity induced by sample handling,
and to analyze the prevalence of CIC as a function
of storage time. Spontaneous aggregation of mono-
meric IgG would probably be the major reactant
that would produce false-positive test results. This
could artificially raise the prevalence of CIC in our
study population and thus render all interpretation
invalid. We found no suggestion of storage-induced
errors in analysis, however. Woodroffe et al [1] ana-
lyzed preformed complexes in serum samples sub-
jected to repeated freeze-thawing and failed to dem-
onstrate a storage-induced increase in assay reac-
tivity. The prevalence of CIC in MN in the patients
presented here is so similar to that presented by So-
bet et al [11] for a prospective study of sera stored
fresh at —80° C for short periods of time, that it
seems unlikely that all of our results represent stor-
age artefact. We recognize, however, that storage-
induced positivity has not been rigorously excluded
because of the lack of concurrent control normal
sera.
The careful followup and documentation of clini-
cal course in the present study allowed correlation
of CIC results with clinical aspects of disease. In all
three histologic categories, there was no correlation
of assay positivity with rate of change of GFR,
"stop points," or remission of the nephrotic syn-
drome. There also was no correlation of CIC results
with treatment group, nor was prednisone therapy
at the dose used associated with a change in assay
positivity for individual assays or the panel of as-
says. Thus, the detection of CIC has no apparent
clinical correlates that would be of value in predict-
ing histologic lesion, prognosis, or remission of the
nephrotic syndrome. Careful correlation between
serologic data and specific categories of patients
may provide clinically useful data, as Levinsky et al
[15] and Smith et al [16] have suggested for children
with MCD.
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Although glomerular deposits of immunoglobulin
and complement suggest an immune complex path-
ogenesis for some forms of glomerulonephritis, the
pathogenic significance of detected CIC is yet to be
determined. It is possible that CIC are epi-phe-
nomena" and bear no relationship to the associated
disease. Immune complexes that are detected in the
circulation may represent those that are left behind
after some other constituents of plasma (maybe
circulating free antigen or antibody) have deposited
in the glomerulus. It is possible that glomerulone-
phritis, which is associated with but not causally re-
lated to the presence of CIC, occurs in the presence
of a primary defect in immune function. dC may
have a pathogenic role other than by direct deposi-
tion and local inflammation. Immune complexes
may influence intravascular vasoactive amines,
platelet aggregation, complement activation, and
coagulation that exert physiologic consequences in-
dependent of tissue deposition of CIC. Proteinuna
of MCD may be initiated by this mechanism. An
immune complex pathogenesis of many forms of
glomerulonephritis has been accepted primarily on
the basis of the pattern of immunoglobulin deposi-
tion. Although the presence of CIC is necessary for
the support of this hypothesis, this does not alone
confirm that they deposit intact in the glomerulus.
Confirmation of an identical antigen and antibody
composition for the CIC and deposited material is
important. Further definition of factors that influ-
ence deposition and inflammation is necessary. This
study approaches only the first step in the definition
of the role of CIC in the pathogenesis of idiopathic
nephrotic syndrome.
Acknowledgments
This study was presented in part at the annual
meeting of the American Society of Nephrology,
1977 and published in abstract form. This work was
supported by National Institutes of Health Grant
Nos. AM 15646 and RR00425 and RR-3 from the
Division of Research Resources. It was supported
in part by NIH-AM 18729; UHPHS 5-MOL-RR-
00058, Clinical Research Center, UHPHS ilL-
05949 Training Grant in Nephrology and Hyper-
tension; NIH 5 T32 AM07241-02 Training Grant in
Nephrology, Peter Bent Brigham Hospital; Re-
search Career Award 5K0 HL 4418, (to Dr. Spar-
go); USPHS RR-109, University of Vermont, Clini-
cal Research Center; and a gift from Dr. Arthur Riv-
in. Dr. Abrass and Dr. Brown were supported as
research fellows of the National Kidney Founda-
tion. P. Miles and D. Strong gave technical assist-
ance, K. Anderson and M. Norton typed the manu-
script, and Dr. M. Fox performed the statistical
analyses.
Reprint requests to Dr. C. K. Abrass, Division of Nephrology,
Veterans Administration Medical Center, 16111 Plummer Street,
Sepulveda, California 91343, USA
References
I. WOODROFFE AJ, BORDER WA, THEOFILOPOULOS AN.
GOTZE 0. GLASSOCK Ri, DIXON FJ, WILSON CB: Detection
of circulating immune complexes in patients with glomerulo-
nephritis. Kidney mt 12:268—278, 1977
2. C000iNs CH. and the Collaborative Study of the Adult
Idiopathic Nephrotic Syndrome: A controlled study of
short-term prednisone treatment in adults with membranous
nephropathy. Nephron 24:10, 1979
3. THEOFILOPOULOS AN, WILSON CB, DIXON FJ: The Raji cell
radioimmunoassay for detecting immune complexes in hu-
man sera. J Cli,, Invest 57: 169—182, 1976
4. BROWN CA, HALL CL, LONG JC, CAREY K, WEITZMAN
SA, AINSENBERG AD: Circulating immune complexes in
Hodgkin's disease. A,n J Med 64:289—294, 1978
5. NYDEGGER UE, LAMBERT PH, GERBER H, MIESCHER PA:
Circulating immune complexes in the serum in systemic
lupus erythematosus and in carriers of hepatitis B antigen
quantitation by binding to radiolabeled Clq. J Cli,, Invest
34:297—309. 1974
6. YONEMASU K, STROUD RM: Clq: Rapid purification method
for preparation of monospecific antisera and for biochemical
studies. J Im,nunol 106:304—313, 1971
7. MCCONAHEY PH, DIXON Fl: A method for trace iodination
of proteins for immunologic studies. Im' Arch Allergy
29:185—189, 1966
8. HAY FC. NINEHAM U. ROITT IM: Routine assay for the
detection of immune complexes of known immunoglobulin
class using solid phase Clq. Clin Exp Immunol 24:396-400.
1976
9. MAUER SM, FISH AJ. BLAU EB. MICHAEL AF: The gb-
merular mesangium: I. Kinetic studies of macromolecular
uptake in normal and nephrotic rats. J Cliii Invest 51:1092—
1100. 1972
10. STUHLINGER WD. VERROUST PJ, MOREL-MAROGER L: De-
tection of circulating soluble immune complexes in patients
with various renal diseases. Immunology 30:43-47, 1976
11. SOBEL A, GABAY Y. LAGRUE G: Recherche de complexes
immunocirculants par Ic test de deviation de la fraction Clq
du complement: Premieres applications a l'etude des glome-
rulopathies humaines. Nouv Presse Med 5:1465—1467, 1976
12. SIMPSON Ii, DOAK PB, WILLIAMS LC, WARD BG. NORTH
JDK: Circulating immune complexes in primary glomerulo-
nephritis and systemic lupus erythematosus. Proc Aust Soc
Nephrol Feb, 1978, p. 20
13. ADAM C, MOREL-MAROGER U, RLCIIET G: Cryoglobulins in
glomerulonephritis not related to systemic disease. Kidney
mt 3:334—341, 1973
14. MCINTOSH RM. GRISWOLD WR. CHERNACK WB, WILLIAMS
G. STRAUSS J, KAUFMAN DB, Koss MN. MCINTOSH RM,
COHEN R, WELL R: Cryoglobulins III: Further studies on the
nature, incidence, clinical, diagnostic, prognostic and immu-
Immune complexes in nephrot:c syndrome 553
nopathologic significance of cryoproteins in renal disease.
Quart J Med 44(174):285—307, 1975
15. LEVINSKY RJ, MALLESON PN,BARRETT TM, SOOTHILL JF:
Circulating immune complexes in steroid-responsive ne-
phrotic syndrome. N EngI J Med 298:126-130, 1978
16. SMITH MD. BARRATT TM, HAYWARD RA, SOOTHILL iF:
The inhibition of complement-dependent lymphocyte rosette
formation by the sera of children with steroid-sensitive
nephrotic syndrome and other renal diseases. C/in Exp 1w-
munol 21:236—243, 1975
17. LAMBERT PH. DixoN FJ, ZUBLER RH, AGNELLO V, CAN-
IBIASO C. CASALI P. CLARKE J. CONDERY JS, MCDUEFIE
FC, HAY FC. MCLENNAN 1CM. MASSON P. MILLER-EBER-
HARD Hi, PENTTINEN K, SMITH M, TAPPEINER GT, THEO-
FILOPOULOS AN, VERROUST P: A collaborative study for the
evaluation of eighteen methods for detecting immune com-
plexes in serum. fLab C/in Immunol 1:1—15, 1978
18. GLUCKMAN JC. BEAUHLS H, SANCHEZ A: Inhibition of
complement-dependent lymphocyte rosette formation by
sera of patients with chronic glomerulonephritis. C/in Exp
Immunol 26:247-252, 1976
19. NEWMAN Wi. FISHER CC, MCCOY RC, GUNNELLS JC,
KRUEGER RP, CLAPP JR. ROBINSON RR: Focal glomerular
sclerosis: Contrasting clinical patterns in children and
adults. Medicine 55:67—87, 1976
20. RossEN RD. RUSBERG MA, SINGER D, SUKIUN. DUFFY J,
HERSH EM, SCHLOEDER FX, HILL LL, EKNOYAN G: The
effect of age on the character of immune complex disease: A
comparison of the incidence and relative size of materials
reactive with Clq in sera of patients with glomerulonephritis
and cancer. Medicine 58:65—79. 1979
21. Ooi YM, 001 BS. POLLAK VE: Relationship of levels of cir-
culating immune complexes to histologic patterns of neph-
ntis: A comparative study of membranous glomerulopathy
and diffuse proliferative glomerulonephritis. f Lab C/in Med
90:891—898. 1977
22. TUNG KSK, WOODROFFEAJ. AHLIN TD, WILLIAMS RC.
WILSON CB: Application of the solid phase Clq and Raji cell
radioimmune assay for the detection of circulating immune
complexes in glomerulonephritis. J C/in Invest 62:61—72,
1978
23. ZAGER RA, COUSER WG, ANDREWS BS. BOLTON WK,
POHL MA: Membranous nephropathy (MN): A search for
anti-renal tubuloepithelial antibodies (RTE-AB) and circu-
lating immune complexes (ClCs). Kidney hit 14:668, 1978
24. VAN Es LA. BLOK APR, SCHOENFELD L. GLAS5OCK Ri:
Chronic nephritis induced by antibodies reacting with gb-
merular bound immune complexes. Kidney Int 11:106-115,
1977
25. VAN DAMME B, FLEUREN GJ, BAKKER WE, VERNIER RL.
HOEDEMAEKER Pi: Experimental glomerulonephritis in the
rat induced by antibodies directed against tubular antigens:
V. Fixed glomerular antigens in the pathogenesis of heterol-
ogous immune complex glomerulonephnitis. Lab Invest
38:502—510, 1978
26. COUSER WG, STEINMULLER DR. STILMANT MM. SALANT
Di. LOWENSTEIN LM: Experimental glomerulonephritis in
the isolated perfused rat kidney. iC/in Invest 62:1275- 1287,
t978
27. Ooi YM, VALLOTA EH, WEST CD: Serum immune com-
plexes in membranoproliferative and other glomerulonephri-
tides. Kidney mt 11:275—283,1977
28. CASALI P. BossUs A, CARPENTIERNA. LAMBERTPH: Solid
phase enzyme immunoassay or radioimmunoassay for the
detection of immune complexes based on their recognition
by conglutinin: Conglutinin binding test. A comparative
study with 1251 labeled Clq binding and Raji cell RIA tests.
C/in Exp Immunol 29:342—354, 1977
